Eli Lilly (NYSE:LLY) shares have pulled back sharply, falling  9% over the past month, and 13% year-to-date. Most Wall Street ...

Since investment bank HSBC downgraded the stock of Eli Lilly from “hold” to “reduce” on Tuesday morning, the share price of ...

What HSBC just said about Eli Lilly stock. Well, technically, the word HSBC used was "reduce," but it amounts to the same ...

Eli Lilly (LLY) stock declined after HSBC downgrade to Reduce with $850 price target, citing obesity drug market risks and ...

Eli Lilly (LLY) shares slipped in the premarket on Tuesday after HSBC downgraded the weight loss drugmaker to Reduce from Hold, issuing the pharma giant’s only sell-equivalent rating on Wall Street, ...

Rajesh Kumar, HSBC Sr. health care analyst, joins CNBC's 'Money Movers' to discuss his reaction to a board shakeup at Novo Nordisk. Got a confidential news tip? We want to hear from you. Sign up for ...

Rajesh Kumar, head of European life sciences & healthcare equity research at HSBC, joins BNN Bloomberg to discuss the bank's ...

HSBC has downgraded Eli Lilly to Reduce, arguing in a note on Tuesday that expectations for the fast-growing obesity drug ...

Eli Lilly, the maker of Zepbound and Mounjaro, faces stiff price competition in the coming year, HSBC says.

Analysts say pricing pressure and competition could limit market growth to $80B--$120B, below consensus expectations above $150B.

Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) +4.3% in Wednesday's trading to reach an eight-month high after scoring analyst upgrades to Buy at both HSBC and Kepler Cheuvreux with respective €32 and €33 price ...